Cancer Biopsy Market - Global Growth, Trends and Forecast (2022 - 2027) By Types, By Application, By Regions and By Key Players: Qiagen N.V., Illumina, Inc., ANGLE Plc, Myriad Genetics, Hologic, Inc., Biocept, Inc.

The market for Cancer Biopsy was valued at US$ 25.75 billion in 2021, and it is anticipated to increase to US$ 66.5 billion by 2027, with a CAGR of 17.9% during 2022 and 2027.

Cancer Biopsy Market Overview

A biopsy is the process of removing tissue in order to examine it for disease. Tissue samples can be taken from any part of the body. Numerous techniques can be used to do biopsies. Some biopsies involve physically removing a suspicious mass or nodule, while others involve collecting a small sample of tissue with a needle. Imaging tests like MRIs and CT scans can help find lumps or abnormal tissue, but they are unable to tell malignant cells from non-cancerous ones. Taking a biopsy and collecting cells for additional examination is the sole way to diagnose the majority of cancers.

The rise of the cancer biopsy market is projected to be fueled by the ageing global population and the increased incidence of cancer symptoms. The development of liquid biopsy techniques is also anticipated to advance the cancer biopsy industry. Many techniques, including skin, needle, bone marrow, endoscopic, and surgical biopsies, are widely utilized in the field of oncology diagnostics. Among these methods, needle biopsies are recognized as a preferred tool for patient early detection. However, advantages of fine needle aspiration needle biopsies, including decreased invasion and quicker results, have led to an expansion of the cancer biopsy industry. Globally, there are now a much greater number of people who have cancer. Some of the factors contributing to the rise in cancer cases include environmental factors, cigarette smoking, infectious disorders including Hepatitis B and C, as well as lifestyle changes. Liquid biopsy has several benefits over conventional cancer diagnostic techniques, including lower cost, early prognosis, therapy monitoring, tumor heterogeneity discovery, acquired drug resistance, and patient comfort (by eliminating the need for surgery). In conjunction with the rise in cancer prevalence, it is therefore projected that preference for liquid biopsies will rise during the projection period.

Industry News and Updates

March 28, 2019: QIAGEN launches novel liquid biopsy solutions and NGS panels with seamlessly integrated bioinformatics to support advances in cancer research --

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of new solutions designed to advance cancer research as part of its highlights at the American Association for Cancer Research (AACR) 2019 Annual Meeting from March 29 to April 3, 2019, in Atlanta, Georgia. More than 30 studies being presented at AACR 2019 cite molecular testing tools from QIAGEN’s Sample to Insight portfolio.

What are the major Applications, Types and Regions for Cancer Biopsy Market?

Market is segmented based on the type, applications, companies and regions.

By Type, it is segmented into

• Tissue Biopsies


• Liquid Biopsies


• Others

By Application, it is segmented into

• Breast Cancer


• Colorectal Cancer


• Cervical Cancers


• Lung Cancers


• Prostate Cancers


• Skin Cancers


• Blood Cancers


• Kidney Cancers


• Others

Cancer Biopsy Market Regional Analysis

In 2020, North America had the largest share (more than 40.0%). With the U.S. significantly contributing to regional revenue, the region is expected to maintain its lead during the projected period. Additionally, companies working in this region that distribute and create new kits with applications for rapid diagnostics are their main goals.

Furthermore, the lucrative techniques outlined by the relevant government authorities have been a major factor in the growing use of liquid biopsies across the United States. The framework, which the US Food and Drug Administration created in recent years, serves as the foundation for regulatory policies for liquid biopsy-based oncology diagnostics (FDA). The rules governing enrichment biomarkers, companion diagnostics, and approval precedents make up this framework. The FDA's approval of tests established under the Clinical Laboratory Improvement Amendment (CLIA) has added value to the regulatory paths for liquid biopsy.

• North America
  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East & Africa
  
  
  • Latin America
  
  
  
  

The Cancer Biopsy Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Cancer Biopsy Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.

What is our Cancer Biopsy Market report scope?

Key Takeaways from this Cancer Biopsy Market Report

• Evaluate Cancer Biopsy market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level - for product types, end use applications and by different industry verticals.


• Understand the different dynamics influencing the market - growth driving factors, specific challenges and hidden opportunities.


• Get in-depth insights on your competitor performance – revenue, shares, business strategies, financial benchmarking, product benchmarking, SWOT analysis and more.


• Analyze the sales and distribution channels across geographies to enhance top-line revenues.


• Understand the demanding supply chain with a deep dive on the value augmentation at each, in order to optimize value and bring efficiencies in your processes.


• Get a quick outlook on the Cancer Biopsy market entropy - M&A's, deals, partnerships, product launches of all key players for the past 4 years.


• Evaluate the import-export statistics, supply-demand and competitive landscape for more than top 20 countries globally for the market.

Frequently Asked Questions

What is the growth rate of Cancer Biopsy Market?

The Cancer Biopsy Market is growing at a CAGR of 17.9% over the next 5 years.

Who are the key players in Cancer Biopsy Market?

Qiagen N.V., Illumina, Inc., ANGLE Plc, Myriad Genetics, Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher, Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health, Exact Sciences Corporation, Freenome Holdings, Inc., Oncimmune, Chronix Biomedical, Inc., Personal Genome Diagnostics Inc., Bio-Rad Laboratories Inc., Agena Bioscience Inc., Exosome Diagnostics Inc., F. Hoffmann-La Roche Ltd

What are the significant types of Cancer Biopsy Market?

Tissue Biopsies, Liquid Biopsies, Others

What are the major end-use applications of Cancer Biopsy Market?

Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Others

All our reports are custom made to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report as your needs.